文献速递心脏核医学

18F-FDOPA PET/CT 显像评估心力衰竭患者心脏交感神经功能障碍:一项先导研究

Imaging of cardiac sympathetic dysfunction with 18F-FDOPA PET/CT in patients with heart failure: a pilot study.
PubMed 文献 · J Nucl Cardiol · 2022-12-06

本研究纳入24例健康对照和24例确诊心力衰竭患者,行心脏18F-FDOPA PET/CT,评估心脏自主神经功能障碍的可行性。心衰患者心肌18F-FDOPA摄取显著低于对照(整体降低32.4%±9.5%),LV/M≤1.68鉴别敏感度100%、特异度95.8%。随访中症状恶化或死亡者变异系数较高,但差异未达统计学显著(P=.069)。

要点

  • 心衰患者心肌18F-FDOPA摄取较对照整体降低32.4%±9.5%,心尖部降低最明显(39.9%±7.0%)。
  • LV/M≤1.68可区分心衰与对照,敏感度100%、特异度95.8%。
  • 随访中恶化或死亡者变异系数较高,但差异未达统计学显著(P=.069)。

核心结论

  • 心衰患者心肌18F-FDOPA摄取显著降低,射血分数较低者降低更明显。
  • 变异系数作为区域异质性标志物,可能是潜在的预后指标。

研究设计与样本

  • 先导研究,纳入24例对照(46.5±11.1岁,16例男性)和24例按Framingham标准确诊的心衰患者(43.5±11.0岁,18例男性),均行心脏PET/CT。
  • 在左心室整体心肌、各室壁及纵隔勾画感兴趣区,变异系数由各室壁计数计算。

主要发现

  • 心衰患者心肌18F-FDOPA摄取显著低于对照(P<.001,独立样本t检验),整体降低32.4%±9.5%,心尖部降低最明显(39.9%±7.0%)。
  • LV/M≤1.68区分心衰与对照的敏感度为100%、特异度为95.8%。
  • LV/M与射血分数呈正相关(Pearson系数=0.460,P=.031)。
  • 随访期间3例失访、4例死亡(生存期20.5±4个月)、2例恶化、15例稳定或轻度改善。
  • 恶化或死亡者变异系数高于稳定或改善者(0.16±0.05 vs 0.11±0.05,P=.069,独立样本t检验;Cox回归P=.084),差异未达统计学显著。

关键数值与推荐

  • LV/M≤1.68区分心衰与对照的敏感度100%、特异度95.8%。
  • 心衰患者心肌18F-FDOPA摄取整体降低32.4%±9.5%,心尖部降低39.9%±7.0%。
  • LV/M与射血分数相关(Pearson系数=0.460,P=.031)。
  • 恶化或死亡者变异系数0.16±0.05 vs 稳定或改善者0.11±0.05(P=.069;Cox回归P=.084)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Routine use of cardiac sympathetic imaging in HF has been limited by the lower availability/sensitivity of radiotracers. This study was aimed to assess the feasibility of 18F-FDOPA (commonly available PET-radiotracer) in assessment of cardiac autonomic dysfunction. METHODS: Twenty-four controls (46.5 ± 11.1 years, 16men) and 24 patients (43.5 ± 11.0 years, 18men) with diagnosed HF (Framingham-Criteria) underwent cardiac-PET/CT. Region(s) Of Interest were drawn over entire left ventricular myocardium (LV), individual walls, and mediastinum (M). Coefficient of Variation (CV) was calculated from individual wall counts. RESULTS: HF patients had significantly lower myocardial 18F-FDOPA uptake (P < .001, independent t test) than controls [32.4% ± 9.5% global reduction; highest in apex (39.9% ± 7.0%)]. A cut-off of LV/M ≤ 1.68 could differentiate patients from controls with sensitivity and specificity of 100% and 95.8%, respectively. LV/M correlated positively with EF (Pearson coefficient = 0.460, P .031). During follow-up, 3 patients were lost to follow-up, 4 died (survival-20.5 ± 4 months), 2 worsened, and 15 remained stable/showed mild improvement. Patients who worsened/died during follow-up had higher CV than those with stable/improving symptoms [0.16 ± 0.05 vs 0.11 ± 0.05, P value .069 (independent t test); Cox regression P = .084]. CONCLUSION: Myocardial 18F-FDOPA uptake in patients with HF is significantly reduced. Higher reduction is seen in those with lower EF. CV, a maker of regional heterogeneity, is a potential prognostic marker.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Thanigainathan T, Sharma A, Patel C, et al. Imaging of cardiac sympathetic dysfunction with 18F-FDOPA PET/CT in patients with heart failure: a pilot study. J Nucl Cardiol. 2022. PMID: 36474068. doi:10.1007/s12350-022-03150-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。